Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gay

Showing results (351-360 of 392) with videos related to

Pageof 40
Sort By:
JCO Precision Oncology|October 30, 2025
Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i>-Mutant Transformed Small Cell Lung CancerAlissa J Cooper, Benjamin Herzberg, Mitchell Parma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2026
YAP1 defines an emergent, plastic population of relapsed small cell lung cancerC Allison Stewart, Kavya Ramkumar, Runsheng Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANSBingnan Zhang, Laura Alder, Samuel Rosner, et al.
JTO Clinical and Research Reports|March 31, 2025
Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNASimon Heeke, Saumil Gandhi, Hai T Tran, et al.
European Urology|January 22, 2020
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the BladderAndrea Necchi, Russell Madison, Daniele Raggi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2024
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinomaKelsey L Corrigan, Ting Xu, Yuki Sasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2013
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinomaJeffrey S Ross, Kai Wang, Laurie M Gay, et al.
Nature Cancer|February 1, 2021
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancerC Allison Stewart, Carl M Gay, Yuanxin Xi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2024
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature ReviewYang Xia, Kaiwen Wang, Jing Zhao, et al.
British Journal of Cancer|April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancerMelissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
Pageof 40

Showing results (351-360 of 392) with videos related to

Sort By:
Pageof 40
JCO Precision Oncology|October 30, 2025
Multi-Institution Analysis of Tarlatamab for the Treatment of <i>EGFR</i>-Mutant Transformed Small Cell Lung CancerAlissa J Cooper, Benjamin Herzberg, Mitchell Parma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2026
YAP1 defines an emergent, plastic population of relapsed small cell lung cancerC Allison Stewart, Kavya Ramkumar, Runsheng Wang, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANSBingnan Zhang, Laura Alder, Samuel Rosner, et al.
JTO Clinical and Research Reports|March 31, 2025
Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNASimon Heeke, Saumil Gandhi, Hai T Tran, et al.
European Urology|January 22, 2020
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the BladderAndrea Necchi, Russell Madison, Daniele Raggi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2024
Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinomaKelsey L Corrigan, Ting Xu, Yuki Sasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2013
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinomaJeffrey S Ross, Kai Wang, Laurie M Gay, et al.
Nature Cancer|February 1, 2021
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancerC Allison Stewart, Carl M Gay, Yuanxin Xi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2024
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature ReviewYang Xia, Kaiwen Wang, Jing Zhao, et al.
British Journal of Cancer|April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancerMelissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
Pageof 40